Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study (Q78445240)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12406005%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

title

Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12406005%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

1 reference

M Itälä

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12406005%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

C H Geisler

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12406005%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

E Kimby

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12406005%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

E Juvonen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12406005%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

G Tjonnfjord

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12406005%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

K Karlsson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12406005%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

K Remes

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12406005%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

publication date

1 September 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12406005%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Haematology

14 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12406005%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

volume

69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12406005%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12406005%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

page(s)

129-134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12406005%20AND%20SRC:MED&resulttype=core&format=json

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

14 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02786.X

Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02786.X

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02786.X

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02786.X

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02786.X

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02786.X

Rituximab dose-escalation trial in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02786.X

Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02786.X

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02786.X

Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02786.X

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02786.X

Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02786.X

10.1034/J.1600-0609.2002.02786.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12406005%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

1 reference